Education
About Us
Working with TipRanks
Follow Us
Bluebird bio Inc (DE:BLE0)
:BLE0
BLE0 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€3.36 - €25.45
Previous CloseN/A
Volume200.00
Average Volume (3M)45.00
Market Cap
€35.89M
Enterprise Value€390.74M
Total Cash (Recent Filing)$131.84M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 07, 2025EPS Estimate
-2.9Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,790,070
10 Day Avg. Volume102
30 Day Avg. Volume45
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.16
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap10.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-70.11
Enterprise Value/Ebitda-3.05
Forecast
1Y Price Target
€5.29Price Target Upside43.70% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
PrivatizationThe announced privatization of the company is expected to be completed within the first half of 2025.
Sales GrowthThe company's portfolio is expected to reach over $600 million in annual sales, triggering a potential cash value right.
Treatment ReachBLUE has activated more than 70 QTCs for Zynteglo and Lyfgenia, indicating a broader treatment reach.
Bears Say
Financial Performance3Q24 revenue of $10.6mm was below the expected $21.1mm and continues to decline sequentially QoQ from $16.1mm in 2Q24 and $18.6mm in 1Q24.
Market ConfidenceThe company has been moved to a Neutral rating from Underweight, indicating less confidence in outperforming the market.
Profitability ChallengesBluebird was reaching the end of its cash runway, unlikely to achieve near-term profitability from its ongoing commercial launches, and at risk of defaulting on its loan covenants.
---
Options Prices
Currently, No data available
---
Ownership Overview
9.55% Insiders
11.51%
Mutual Funds
3.53% Other Institutional Investors
65.34% Public Companies and
Individual Investors
BLE0 FAQ
What was Bluebird bio Inc’s price range in the past 12 months?
Bluebird bio Inc lowest stock price was €3.36 and its highest was €25.45 in the past 12 months.
What is Bluebird bio Inc’s market cap?
Bluebird bio Inc’s market cap is €35.89M.
When is Bluebird bio Inc’s upcoming earnings report date?
Bluebird bio Inc’s upcoming earnings report date is May 07, 2025 which is in 11 days.
How were Bluebird bio Inc’s earnings last quarter?
Currently, no data Available
Is Bluebird bio Inc overvalued?
According to Wall Street analysts Bluebird bio Inc’s price is currently Undervalued.
Does Bluebird bio Inc pay dividends?
Bluebird bio Inc pays a Notavailable dividend of €156.038 which represents an annual dividend yield of N/A. See more information on Bluebird bio Inc dividends here
What is Bluebird bio Inc’s EPS estimate?
Bluebird bio Inc’s EPS estimate is -2.9.
How many shares outstanding does Bluebird bio Inc have?
Bluebird bio Inc has 9,790,070 shares outstanding.
What happened to Bluebird bio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bluebird bio Inc?
Currently, no hedge funds are holding shares in DE:BLE0
---
Bluebird Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€5.29 (43.70% Upside)
€5.29 (43.70% Upside)
Blogger Sentiment
Bullish
DE:BLE0 Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $11.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.46%
12-Months-Change
Fundamentals
Return on Equity
-295.35%
Trailing 12-Months
Asset Growth
-25.67%
Trailing 12-Months
Company Description
Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
---
BLE0 Stock 12 Month Forecast
Average Price Target
€5.29
▲(43.70% Upside)
Technical Analysis
Adicet Bio
―
Precision BioSciences
―
Repare Therapeutics
―
Ikena Oncology
―
Immuneering
―
Best Analysts Covering BLE0
1 Year
1 Year Success Rate
11/24 ratings generated profit
1 Year Average Return
+26.20%
reiterated a buy rating 29 days ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 45.83% of your transactions generating a profit, with an average return of +26.20% per trade.
---